Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80)
Authors
Antonio González-Martı́n (ORCID: https://orcid.org/0000-0001-8376-9576)
Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80)
Antonio González-Martı́n, Ruby Yun‐Ju Huang, Ka Yu Tse, Eun-Jeong Yang et al.
Citations
7 citations
Journal
Journal of Gynecologic Oncology
Topics
Ovarian cancer diagnosis and treatment
Field-Weighted Citation Impact (FWCI)
3.76
article
Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80)
Antonio González-Martı́n, Ruby Yun‐Ju Huang, Ka Yu Tse, Eun-Jeong Yang, David S.P. Tan, Jung‐Yun Lee, Els Van Nieuwenhuysen, Clare L. Scott, Kosei Hasegawa, Rebecca Kristeleit, Katie Wilkinson, Isabelle Ray‐Coquard, Stéphanie Lheureux, Byoung Gie Kim, Jung Bok Lee
article en
7 citations
Abstract
No abstract available for this paper.
Publication Tag
Journal of Gynecologic OncologyVol. 36(1)
Institutions
Université Claude Bernard Lyon 1 (FR), Inserm (FR), National Taiwan University (TW), Chinese University of Hong Kong (HK), King's College London (GB), Yonsei University (KR), Guy's and St Thomas' NHS Foundation Trust (GB), Severance Hospital (KR), Peter MacCallum Cancer Centre (AU), Samsung Medical Center (KR), Princess Margaret Cancer Centre (CA), University of Ulsan (KR), National University Cancer Institute, Singapore (SG), Centre Léon Bérard (FR), Health Services and Performance Research Laboratory (FR), Clinica Universidad de Navarra (ES), National University Hospital (SG), CRUK Lung Cancer Centre of Excellence (GB), Research on healthcare performance (FR), University College London (GB), Saitama Medical University (JP), University of Hong Kong (HK)
Funders
Amgen, AstraZeneca, GlaxoSmithKline, Sanofi, Kimberly-Clark, Karyopharm Therapeutics, Regeneron Pharmaceuticals, Novocure, Clovis Oncology, Mersana Therapeutics, BeiGene, Incyte, MacroGenics, Seagen, National Research Foundation, National University of Singapore, National Research Foundation of Korea, Eisai, PharmaMar, Ministry of Science and ICT, South Korea, Sierra Oncology, Chugai Pharmaceutical, Medical Research Council, National Medical Research Council, Daiichi Sankyo Europe